Qube Research & Technologies (QRT)
NBIX icon

Qube Research & Technologies (QRT)’s Neurocrine Biosciences NBIX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-91,514
Closed -$13M – 3919
2025
Q4 		$13M Buy
+91,514
New +$13.3M 0.01% 1168
2025
Q1 		– Sell
-145,111
Closed -$19.8M – 3740
2024
Q4 		$19.8M Sell
145,111
-618,244
-81% -$76.5M 0.03% 725
2024
Q3 		$88M Buy
763,355
+161,635
+27% +$22.2M 0.13% 174
2024
Q2 		$82.8M Buy
601,720
+349,889
+139% +$48M 0.13% 181
2024
Q1 		$34.7M Buy
251,831
+82,221
+48% +$11.2M 0.06% 406
2023
Q4 		$22.3M Buy
169,610
+33,840
+25% +$3.9M 0.04% 473
2023
Q3 		$15.3M Sell
135,770
-92,695
-41% -$9.76M 0.04% 490
2023
Q2 		$21.5M Sell
228,465
-73,798
-24% -$7.21M 0.08% 323
2023
Q1 		$30.6M Buy
302,263
+79,446
+36% +$8.27M 0.13% 172
2022
Q4 		$26.6M Buy
222,817
+214,655
+2,630% +$25.1M 0.14% 195
2022
Q3 		$867K Buy
+8,162
New +$828K 0.01% 1253
2022
Q1 		– Sell
-70,739
Closed -$6.03M – 2808
2021
Q4 		$6.03M Buy
+70,739
New +$6.51M 0.05% 498
2021
Q3 		– Sell
-45,085
Closed -$4.39M – 2581
2021
Q2 		$4.39M Buy
+45,085
New +$4.32M 0.05% 448
2021
Q1 		– Sell
-48,046
Closed -$4.61M – 2242
2020
Q4 		$4.61M Sell
48,046
-108,902
-69% -$10.5M 0.07% 338
2020
Q3 		$15.1M Buy
156,948
+121,096
+338% +$14M 0.22% 104
2020
Q2 		$4.37M Buy
35,852
+29,224
+441% +$3.23M 0.06% 397
2020
Q1 		$574K Sell
6,628
-3,332
-33% -$326K 0.02% 525
2019
Q4 		$1.07M Buy
+9,960
New +$1.04M 0.03% 581

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NBIX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 91,514 shares — an estimated $13M sold.

Qube Research & Technologies (QRT) first reported a position in NBIX in Q4 2019 and held it in 18 quarters. The position peaked at $88M in Q3 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 91,514 Neurocrine Biosciences shares in Q1 2026, an estimated $13M.
  • Qube Research & Technologies (QRT) first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 18 quarters.
  • Qube Research & Technologies (QRT)'s Neurocrine Biosciences position peaked at $88M in Q3 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.